BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16282711)

  • 21. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
    Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
    Lin CM; Chen CH; Chang JW; Tsao TC
    Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
    Jiang L; Wang DY; Zhu ZH; Tang LF; Hou XH; Zhao HD; Xie Z; Wang DF
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):449-53. PubMed ID: 19937029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
    Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
    J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ifosfamide/carboplatin/etoposide chemotherapy in patients with metastatic non-small cell lung cancer.
    Chang AY; Asbury RF; Boros L; Garrow GC; Hsieh S
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):9-12. PubMed ID: 7610399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
    Ramalingam S; Dobbs TW; Einzig AI; Wojtowicz-Praga S; Cascino M; Bonomi P; Belani CP
    Cancer Chemother Pharmacol; 2004 May; 53(5):439-44. PubMed ID: 15132135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
    Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
    Belani CP; Einzig A; Bonomi P; Dobbs T; Capozzoli MJ; Earhart R; Cohen LJ; Luketich JD
    Ann Oncol; 2000 Jun; 11(6):673-8. PubMed ID: 10942054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
    Kosmas C; Tsavaris NB; Malamos NA; Vadiaka M; Koufos C
    J Clin Oncol; 2001 Jan; 19(1):119-26. PubMed ID: 11134204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study.
    Jahanzeb M; Sarna G; Hirsch R; Radice P; Koletsky A; Martinez M; Kruglyak E; Wolin E; Camacho E; Kronish L; Motl S
    Anticancer Res; 2004; 24(2C):1239-42. PubMed ID: 15154653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
    Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
    Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
    Ohyanagi F; Yanagitani N; Kudo K; Kawano Y; Sakatani T; Tanimoto A; Nishizawa H; Horiike A; Hagiwara S; Horai T; Nishio M
    Anticancer Res; 2014 Sep; 34(9):5153-8. PubMed ID: 25202107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.